The tables have turned pretty quickly for Israeli-based branded- and generic-drug developer Teva Pharmaceutical Industries (NYSE: TEVA). In July 2015, shares of the company were trading north of $72, an all-time high. Today, Teva’s stock is struggling to hang onto the $30 mark, which is a more than 10-year low for the company.
What went so terribly wrong over the course of less than two years?
Image source: Getty Images.